TCRX TSCAN THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, TSCAN THERAPEUTICS INC reported revenue of $1.05M (down 65.8% from a year earlier), net income of −$30.4M and diluted EPS of −$0.23; over the last four quarters revenue was $7.11M and net income −$118M; for the fiscal year ended December 2025 revenue was $10.3M, up 266.7% on the year before.

TCRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $10.3M, gross profit n/a, operating income −$136M, net income −$130M (margin -1256.8%), EPS −$1.00
• Fiscal year ended Dec 2024: revenue $2.82M, gross profit n/a, operating income −$135M, net income −$127M (margin -4527.7%), EPS −$1.14
• Fiscal year ended Dec 2023: revenue $21.0M, gross profit n/a, operating income −$93.5M, net income −$89.2M (margin -423.9%), EPS −$1.36
• Fiscal year ended Dec 2022: revenue $13.5M, gross profit n/a, operating income −$66.6M, net income −$66.2M (margin -489.3%), EPS −$2.75
• Fiscal year ended Dec 2021: revenue $10.1M, gross profit n/a, operating income −$48.6M, net income −$48.6M (margin -479.5%), EPS −$4.17

TCRX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.05M (down 65.8% year over year), net income −$30.4M, EPS −$0.23
• Quarter ended Mar 31, 2026: revenue $982K (down 54.8% year over year), net income −$28.7M, EPS −$0.22
• Quarter ended Dec 31, 2025 (from the annual report): revenue $2.57M (up 286.0% year over year), net income −$23.0M, EPS −$0.18
• Quarter ended Sep 30, 2025: revenue $2.51M (up 139.4% year over year), net income −$35.7M, EPS −$0.28
• Quarter ended Jun 30, 2025: revenue $3.08M (up 473.9% year over year), net income −$37.0M, EPS −$0.28
• Quarter ended Mar 31, 2025: revenue $2.17M (up 283.6% year over year), net income −$34.1M, EPS −$0.26
• Quarter ended Dec 31, 2024 (from the annual report): revenue $665K (down 90.8% year over year), net income −$35.8M, EPS −$0.29
• Quarter ended Sep 30, 2024: revenue $1.05M (down 73.0% year over year), net income −$29.9M, EPS −$0.25
• Quarter ended Jun 30, 2024: revenue $536K (down 83.0% year over year), net income −$31.7M, EPS −$0.28
• Quarter ended Mar 31, 2024: revenue $566K (down 91.7% year over year), net income −$30.1M, EPS −$0.32
• Quarter ended Dec 31, 2023 (from the annual report): revenue $7.21M (up 133.0% year over year), net income −$19.6M, EPS $0.32
• Quarter ended Sep 30, 2023: revenue $3.89M (up 15.6% year over year), net income −$23.0M, EPS −$0.24
• Quarter ended Jun 30, 2023: revenue $3.15M (down 22.4% year over year), net income −$24.0M, EPS −$0.51
• Quarter ended Mar 31, 2023: revenue $6.80M (up 125.2% year over year), net income −$22.6M, EPS −$0.93
• Quarter ended Dec 31, 2022 (from the annual report): revenue $3.10M (up 8.4% year over year), net income −$18.7M, EPS −$0.78
• Quarter ended Sep 30, 2022: revenue $3.36M (up 39.4% year over year), net income −$16.2M, EPS −$0.67
• Quarter ended Jun 30, 2022: revenue $4.06M (up 42.4% year over year), net income −$15.1M, EPS −$0.63
• Quarter ended Mar 31, 2022: revenue $3.02M (up 49.0% year over year), net income −$16.2M, EPS −$0.67
• Quarter ended Dec 31, 2021 (from the annual report): revenue $2.85M, net income −$14.2M, EPS $10.81
• Quarter ended Sep 30, 2021: revenue $2.41M, net income −$15.8M, EPS −$0.80

TCRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$135M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$111M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$61.4M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$66.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$48.7M, share buybacks n/a

TCRX balance sheet

• Jun 30, 2026: cash $100M, total assets $171M, total liabilities $102M, shareholders' equity $69.0M, long-term debt $21.1M
• Mar 31, 2026: cash $128M, total assets $202M, total liabilities $105M, shareholders' equity $96.9M, long-term debt $32.7M
• Dec 31, 2025: cash $152M, total assets $229M, total liabilities $106M, shareholders' equity $123M, long-term debt $32.5M
• Sep 30, 2025: cash $170M, total assets $262M, total liabilities $118M, shareholders' equity $144M, long-term debt $32.4M
• Jun 30, 2025: cash $169M, total assets $299M, total liabilities $122M, shareholders' equity $177M, long-term debt $32.3M
• Mar 31, 2025: cash $154M, total assets $333M, total liabilities $123M, shareholders' equity $210M, long-term debt $32.2M
• Dec 31, 2024: cash $179M, total assets $371M, total liabilities $130M, shareholders' equity $241M, long-term debt $32.1M
• Sep 30, 2024: cash $133M, total assets $348M, total liabilities $119M, shareholders' equity $229M, long-term debt $30.6M

What is TCRX's revenue?

TSCAN THERAPEUTICS INC reported $7.11M of revenue over its last four quarters, through June 30, 2026.

Is TCRX profitable?

No. TSCAN THERAPEUTICS INC lost $118M over the last four quarters.

What is TCRX's EPS?

Diluted earnings per share over the last four quarters were −$0.91; −$0.23 in the latest quarter.

TCRX ownership and insider trades · All stocks